MétaCan
Menu
Back to cohort
Record W4398185057 · doi:10.1016/j.jaip.2024.05.019

Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study

2024· article· en· W4398185057 on OpenAlexaff
John Oppenheimer, Huib A.M. Kerstjens, Louis‐Philippe Boulet, Nicola A. Hanania, Edward Kerwin, Alison Moore, Robert A. Nathan, Guy Peachey, Emílio Pizzichini, David Slade, Agne Zarankaite, Ian Pavord

Bibliographic record

VenueThe Journal of Allergy and Clinical Immunology In Practice · 2024
Typearticle
Languageen
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsUniversité Laval
FundersSanofi GenzymeSunovionCovis PharmaBoston Scientific CorporationSanofiRegeneron PharmaceuticalsTeva Pharmaceutical IndustriesGenentechAstraZenecaMylanGlaxoSmithKlineAmgen
KeywordsMedicineExacerbationFluticasone propionateAsthmaRandomizationInternal medicineAsthma exacerbationsRandomized controlled trialPopulationSeverity of illnessLung functionCorticosteroidClinical trialLung

Abstract

fetched live from OpenAlex

Background Limited data exist on the relative impact of moderate and severe exacerbations on asthma control and impairment. Objective To explore data from the CAPTAIN trial to evaluate the relationship between first moderate or severe exacerbation and changes in lung function, symptoms, physical activity limitation scores, and short-acting β 2 -agonist (SABA) usage to determine the clinical relevance of moderate events. Methods CAPTAIN was a Phase IIIA 24–52-week, multicenter, international, randomized controlled trial evaluating efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in patients with uncontrolled asthma on inhaled corticosteroid/long-acting β 2 -agonist. Outcomes reportedinclude: first post-randomization exacerbation event by severity (Weeks 1–52), frequency and duration of moderate and severe exacerbations and time course of changes over ±14-day peri-exacerbation period for lung function, symptoms, limitations, and SABA use. Results Of the intent-to-treat population (N=2436), 550 patients (23%) continued to 52 weeks. There were 529 moderate and 546 severe exacerbations. Lung function changes were similar, but symptom, physical activity limitation scores, and SABA use were higher, for severe versus moderate exacerbations. Lung function decline preceded increases in symptom, physical activity limitation scores, and SABA use, irrespective of exacerbation severity. Lung function variables, limitation scores, and SABA use returned to pre-exacerbation baseline after ∼8–12 days for both exacerbation severities. Conclusion While severe events were associated with greater impact on symptoms, physical activity limitations, and SABA use, onset and time to resolution were generally similar for moderate and severe events. Both exacerbation severities represent clinically important deteriorations comprising clinical and functional changes. NCT02924688.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.358
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of Allergy and Clinical Immunology In PracticeSame topicAsthma and respiratory diseasesFrench-language works237,207